Galapagos Cell Therapy: Shut Down

Galapagos stock plunges as it shutters its cell therapy business after failing to find a buyer, even with its former CEO interested. Gilead, a major player in cell therapy and Galapagos' partner, declined to get involved, highlighting the unit's struggles. The move ends months of uncertainty, allowing Galapagos to redirect resources to more promising ventures, but leaves employees in limbo and raises questions about the company's future in a challenging biotech landscape.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.